Kidney Disease Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type (Diagnosis, Treatment); End User (Hospital, Diagnostic Laboratories, Others), and Geography
Publication Month: Sep 2020 | Report Code: TIPRE00014589 | No. of Pages: 215 | Category: Pharmaceuticals | Status: Published
The kidney disease market is expected to reach US$ 133,444.71 million by 2027 from US$ 81,128.11 million in 2019. The market is estimated to grow with a CAGR of 6.5% from 2020 to 2027.
Policy-makers have to ensure that an appropriate mix of pharmaceutical policy options is implemented to meet equitable, affordable, and sustainable access to medicines as well as medical care. The World Health Organization has projected various strategies to support policy-makers in developing suitable policies, including the concept of the vital medicine list and the universal health coverage (UHC) approach. Moreover, European countries with advanced UHC and social protection systems have developed pharmaceutical pricing and reimbursement systems that intend to offer various crucial medicines to their citizens at no or reduced cost. For instance, Armenia ensures 100% reimbursement for medicines for specific diseases such as TB, mental health diseases, diabetes, and chronic kidney failure.
In May 2019, VELTASSA, a prescription medication used to treat high potassium levels in the blood (hyperkalemia), has secured reimbursement in Germany, after the completion of AMNOG process (price negotiation and arbitration process). Moreover, reimbursement for the drug was secured in Finland, Austria, Portugal, Spain, Belgium, and a favorable recommendation was received from the National Institute for Health and Care Excellence in the UK. Furthermore, at the end of 2019, VELTASSA was launched in Sweden, Norway, Denmark, Belgium, Germany, Spain, The Netherlands, and Austria. Besides, in 2018, Vifor Pharma announced a licensing agreement with Zeria Pharmaceutical Co., Ltd. to catalyze the process of VELTASSA’s regulatory and reimbursement approval in Japan. Further, in December 2019, China’s National Healthcare Security Administration (NHSA) included Roxadustat in the updated National Reimbursement Drug List (NRDL). The drug Roxadustat is included in the NRDL for the treatment of anemia in CKD (Chronic Kidney Disease). Such lucrative reimbursement policies are likely to accelerate the growth of the market during the forecast period.
Lucrative Regional Markets for Kidney Disease
Get more information on this report :
Market Insights
High Prevalence of Chronic Diseases Leading to Kidney Diseases
Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. High blood pressure and diabetes were the two major causes in 75% of kidney failure cases between 2015 and 2017. Moreover, according to a study published by National Kidney Foundation in 2020, around 35.0% of the diabetic population above age 20 years would develop chronic kidney disease over the period of time.
As per the data published by National Kidney Foundation Inc., in 2020, CKD is likely to cause more deaths than prostate cancer or breast cancer. It is an under-recognized emergency health condition among people. 1 in 3 American adults (about 80 million people) is at risk due to CKD.
According to the estimates given by the Centers of Disease Control and Prevention (CDC) in 2020, 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. In 2015, 30.3 million people in the US had diabetes as per the American Diabetes Association. According to the CDC, in 2014, around 118,000 people in the US started the treatment for end-stage renal disease, and the number of people taking this treatment is expected to increase as more people become aware of this condition. Moreover, the CDC states that around 96% of the people with kidney damage are not aware of having chronic kidney disease, which indicates the underlying market prospective in the kidney disease market. These factors are expected to enhance market growth during the forecast period.
Product TypeInsights
Based on product type, the kidney disease market is segmented into diagnosis and treatment. In 2019, the diagnosis segment accounted for the largest share of the market. Growth of this segment is attributed to increase inblood tests, urine tests, and different imaging procedures.
Global Kidney Disease Market, by Product– 2019 and 2027
Get more information on this report :
End UserInsights
Based on end user, the global kidney disease market is segmented into hospitals, diagnostic laboratories, and others. In 2019, the hospitals segment held a major share of the market and the same segment is anticipated to register the highest CAGR in the market during the forecast period.
Strategic Insights
Product launches and approvalsare the commonly adopted strategies by companies to expand their global footprintsand product portfolios tomeet the growing consumer demand. The kidney disease marketplayers adopt the collaborationsstrategy to enlarge customer base worldwide, which also permits them to maintain their brand name globally.
Kidney Disease Market– by Product Type
- Diagnosis
- Blood Tests
- Urine Tests
- Imaging Tests
- Others
- Treatment
- Drug Class
- ACE Inhibitors
- Angiotensin-II Receptor Blockers
- Diuretics
- Others
- Drug Class
Kidney Disease Market– by End User
- Hospitals
- Diagnostic Laboratories
- Others
Kidney Disease Market – by Geography
North America
- US
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of Asia Pacific
Middle East &Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of Middle East &Africa
South and Central America
- Brazil
- Argentina
- Rest of South America
Company Profiles
- Abbott
- F. Hoffmann-La Roche Ltd.
- AbbVie's Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Amgen Inc.
- Sysmex Corp.
- Fresenius Medical Care SE & Co. KGaA
- Siemens Healthineers AG
Frequently Asked Questions
The List of Companies - Kidney Disease Market
- Abbott
- F. Hoffmann-La Roche Ltd.
- AbbVie's Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Amgen Inc.
- Sysmex Corp.
- Fresenius Medical Care SE & Co. KGaA
- Siemens Healthineers AG
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Kidney disease market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global percutaneous mechanical circulatory support devices market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Get the Latest COVID-19 Analysis on this market
Have a Question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
-
$3000
-
$4550 $3640
-
$6550 $5240
-
$8550 $6840
-
Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.
Inquire for Discount